Tactile Systems Technology, Inc., a medical technology company, is dedicated to the development and supply of medical devices for chronic diseases in the United States. The company is headquartered in Minneapolis, Minnesota.
| Revenue (TTM) | $356.42M |
| Gross Profit (TTM) | $274.46M |
| EBITDA | $40.50M |
| Operating Margin | 10.40% |
| Return on Equity | 11.00% |
| Return on Assets | 7.64% |
| Revenue/Share (TTM) | $15.79 |
| Book Value | $10.10 |
| Price-to-Book | 2.67 |
| Price-to-Sales (TTM) | 1.66 |
| EV/Revenue | 1.543 |
| EV/EBITDA | 12.80 |
| Quarterly Earnings Growth (YoY) | -13.90% |
| Quarterly Revenue Growth (YoY) | 7.10% |
| Shares Outstanding | $22.40M |
| Float | $20.35M |
| % Insiders | 2.28% |
| % Institutions | 105.51% |
Volatility is currently expanding
Tactile Systems Technology (TCMD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TCMD crossed above the 200-day moving average, suggesting a long-term bullish trend.
Tactile Systems Technology is undervalued, trading at a deep discount despite double-digit lymphedema growth and sector-leading 77% gross margins. TCMD's competitive moat widens as Medicare prior authorization requirements increase, favoring scale and established reimbursement infrastructure. LymphaTech acquisition and potential CPT code approval could unlock significant new diagnosis-driven growth, reinforcing TCMD's leadership in lymphedema.
The average of price targets set by Wall Street analysts indicates a potential upside of 52% in Tactile Systems Technology (TCMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
After reaching an important support level, Tactile Systems Technology (TCMD) could be a good stock pick from a technical perspective. TCMD surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Lymphedema product revenue increased 13% year over year to $81.8 million. Technology improvements reduced medical record review times by approximately 50%.
Tactile Systems Technology, Inc. (TCMD) Q3 2026 Earnings Call Transcript
Tactile Systems Technology NASDAQ: TCMD, which operates as Tactile Medical, reported third-quarter revenue of $91.9 million, up 7.1% from a year earlier, as continued double-digit growth in its lymphedema business offset an expected decline in airway-clearance sales tied to distributor inventory transitions.
Lymphedema sales grew at a double-digit pace again, while the smaller airway clearance line shrank. Higher sales and administrative spending pushed operating income below last year's level.
MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2026.
MINNEAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2026 financial results will be released after the market closes on Monday, November 2, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TCMD and any ticker you trade — then tracks every position and per-strategy win rate.
